KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Depreciation & Amortization (CF): 2020-2025

Historic Depreciation & Amortization (CF) for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Sep 2025 value amounting to $21.0 million.

  • Recursion Pharmaceuticals' Depreciation & Amortization (CF) rose 192.35% to $21.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $77.2 million, marking a year-over-year increase of 148.18%. This contributed to the annual value of $36.5 million for FY2024, which is 49.55% up from last year.
  • Per Recursion Pharmaceuticals' latest filing, its Depreciation & Amortization (CF) stood at $21.0 million for Q3 2025, which was down 11.77% from $23.8 million recorded in Q2 2025.
  • Recursion Pharmaceuticals' Depreciation & Amortization (CF)'s 5-year high stood at $23.8 million during Q2 2025, with a 5-year trough of $1.4 million in Q1 2021.
  • Over the past 3 years, Recursion Pharmaceuticals' median Depreciation & Amortization (CF) value was $7.6 million (recorded in 2023), while the average stood at $11.4 million.
  • In the last 5 years, Recursion Pharmaceuticals' Depreciation & Amortization (CF) declined by 5.01% in 2024 and then surged by 192.35% in 2025.
  • Quarterly analysis of 5 years shows Recursion Pharmaceuticals' Depreciation & Amortization (CF) stood at $2.2 million in 2021, then spiked by 43.74% to $3.2 million in 2022, then soared by 135.00% to $7.6 million in 2023, then spiked by 71.47% to $13.0 million in 2024, then surged by 192.35% to $21.0 million in 2025.
  • Its Depreciation & Amortization (CF) stands at $21.0 million for Q3 2025, versus $23.8 million for Q2 2025 and $19.3 million for Q1 2025.